Vildagliptin - Novartis
Alternative Names: Equa; Galvus; Jalra; LAF 237; LAF 237A; NVP LAF 237; NVP LAF 237A; Vysov; XiliarxLatest Information Update: 05 Nov 2023
At a glance
- Originator Novartis
- Developer Cipla; Hanmi Pharmaceutical; Novartis; Samsung Medical Center; University of Sao Paulo
- Class Antihyperglycaemics; Cycloparaffins; Nitriles; Polycyclic bridged compounds; Pyrrolidines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Type 1 diabetes mellitus
Most Recent Events
- 27 Dec 2022 Discontinued - Phase-II for Type 2 diabetes mellitus (Combination therapy) in South Korea (PO)
- 20 May 2021 The CHMP approves change in label and indicates vildagliptin as an adjunct to diet and exercise in adults with Type 2 diabetes mellitus (Combination therapy) in European Union
- 20 May 2021 The CHMP approves change in label and indicates vildagliptin as an adjunct to diet and exercise in adults with Type 2 diabetes mellitus (Monotherapy) in European Union, Iceland and Norway